In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, outlines why faster recruitment, local data requirements for registration, and lower costs make APAC attractive for global Phase III programs.
|Articles|February 25, 2021
Calyx Offers Scientific Consulting
Advertisement
Calyx has announced a scientific consulting program aimed at optimizing imaging processes and outcomes to accelerate the clinical development of new medical treatments.
Calyx Scientific Consulting delivers a range of services to meet the needs of new product development, including:
- Evaluating whether imaging is required based on specific endpoints
- Selecting imaging biomarkers to best demonstrate safety and efficacy at each trial phase
- Choosing the ideal image acquisition strategy to best support biomarker requirements
For more information, click
Advertisement
Related to this article
In today’s ACT Brief, we examine how China’s trial startup timelines compare with those in the US and Europe, whether AI-drafted clinical study reports speed drug development, and how Bimzelx compared with Skyrizi in psoriatic arthritis.
AI can draft a CSR in minutes, but the report only reflects evidence that has already converged, so faster drafting shifts the bottleneck to upstream reconciliation, database-lock readiness, and human accountability rather than shortening the trial itself.
In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, details how NMPA reforms, parallel reviews, and expanded reviewer capacity brought China’s startup timelines in line with the US and Europe, and could shorten them further.
In today’s ACT Brief, we examine why APAC inspection findings mirror those in the US and Europe, how key risk indicators should be read together, and how FDA granted accelerated approval to a subcutaneous antibody therapy for recurrent head and neck cancer.
In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA inspection findings at APAC sites compare with those in the US and Europe, and why the common issues, such as informed consent versioning, are not unique to the region.
In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.
Risk-based quality management depends on knowing what to monitor and on interpreting what the signals mean.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent
2
AI Can Draft the CSR Faster, But Does That Make Drug Development Faster?
3
How China Cut Its Phase III Startup Timeline and What Drove the Change
4
ACT Brief: APAC Inspection Findings, RBQM Key Risk Indicators, and Head and Neck Cancer Approval
5